Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Targeted Therapy
100%
Clinical Potential
100%
Advanced Cholangiocarcinoma
100%
Metastatic Cholangiocarcinoma
100%
Infigratinib
100%
Advanced or Metastatic
100%
Cholangiocarcinoma
50%
Genetic Aberrations
30%
Fibroblast Growth Factor Receptor Inhibitor
30%
Clinical Benefit
20%
Fibroblast Growth Factor Receptor 1 (FGFR1)
20%
FGFR2 Fusion
20%
First-line Therapy
10%
Clinical Trials
10%
Aberrations
10%
Surgical Resection
10%
5-year Survival
10%
Tumor Response
10%
Phase II Trial
10%
Aggressive Tumor
10%
Gemcitabine Plus Cisplatin
10%
Phase 1 Trial
10%
Systemic Therapy
10%
Clinical Development
10%
FOLFIRINOX
10%
Site-directed mutation
10%
Duration of Response
10%
Acquired Resistance
10%
Novel Targeted Agents
10%
First-line Regimen
10%
Safe Profile
10%
Phase 3 Trial
10%
Medicine and Dentistry
Targeted Therapy
100%
Cholangiocarcinoma
100%
Infigratinib
100%
Fibroblast Growth Factor Receptor
50%
Genetics
30%
Fibroblast Growth Factor Receptor 2
20%
Clinical Trial
10%
Cancer
10%
Neoplasm
10%
Immunotherapy
10%
Gemcitabine
10%
Cisplatin
10%
Survival Rate
10%
Systemic Therapy
10%
FOLFOX
10%
Diseases
10%
Pharmacology, Toxicology and Pharmaceutical Science
Bile Duct Carcinoma
100%
Infigratinib
100%
Fibroblast Growth Factor Receptor
50%
Fibroblast Growth Factor Receptor 2
20%
Clinical Trial
10%
Immunotherapy
10%
Neoplasm
10%
Gemcitabine
10%
Cisplatin
10%
Survival Rate
10%
Diseases
10%